• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.13% Nasdaq Up0.70%

    Anacor Pharmaceuticals, Inc. (ANAC)

    -NasdaqGM
    30.75 Up 0.17(0.56%) Dec 26, 4:00PM EST
    |After Hours : 30.75 Up 0.00 (0.01%) Dec 26, 4:42PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Anacor Pharmaceuticals, Inc.
    1020 East Meadow Circle
    Palo Alto, CA 94303
    United States - Map
    Phone: 650-543-7500
    Fax: 650-543-7660
    Website: http://www.anacor.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:79

    Business Summary 

    Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate, which completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis, and chronic inflammatory skin diseases. It also develops AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis; and other compounds to treat animal health indications. The company’s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; AN2898, a topical anti-inflammatory product candidate that completed Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. It has research, development, and collaboration agreements with GlaxoSmithKline LLC, Eli Lilly and Company, Schering Corporation, Medicis Pharmaceutical Corporation, Bill and Melinda Gates Foundation, and Medicines for Malaria Ventures. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Anacor Pharmaceuticals, Inc.

    Corporate Governance 
    Anacor Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Paul L. Berns , 47
    Chairman, Chief Exec. Officer, Pres, Chairman of Compensation Committee, Chairman of Transaction Committee and Member of Audit Committee
    83.00KN/A
    Dr. Lucy Shapiro Ph.D., 73
    Co-Founder, Co-Chair of Scientific Advisory Board, Director and Member of Nominating & Corp. Governance Committee
    37.00KN/A
    Mr. Geoffrey M. Parker , 49
    Chief Financial Officer, Principal Accounting Officer and Exec. VP
    480.00K573.00K
    Dr. Jacob J. Plattner Ph.D., 68
    Sr. VP of Research
    477.00K0.00
    Dr. Lee T. Zane M.D., M.A.S, 44
    Chief Medical Officer and Sr. VP
    482.00K0.00
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders